This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

LeMaitre Vascular, Inc.
11/4/2026
Welcome to the LeMaitre Vascular Q3 2026 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir.
Good afternoon, and thank you for joining us on our Q3 2026 conference call. With me on today's call is our CEO, George LeMaitre. Before we begin, I'll read our Safe Harbor Statement. Today we'll be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risk and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, might, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, November 4th, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures such as organic sales growth, A reconciliation of gap to non-gap measures discussed in this call is contained in the associated press release and in the investor relations section of our website, www.lemaitre.com. I'll now turn the call over to George LeMaitre.
Thanks, Dorian. Sales grew 12% organically in Q3, 7% price and 5% units. Graphs grew 20% and shunts 14%. and Biologics continued to outpace the rest of our portfolio as ArtiGraph was up 18% and Restorfor Allografts 34%. Geographically, EMEA sales increased 18%, the Americas 9% and APAC 5%. On October 14th, we acquired several devices from B. Brown, polyester and silver coated vascular grafts, valve cutters and vein strippers. This is our third polyester graft acquisition since 2007, and we look set to become number three in worldwide share ex-Japan. And we've always wanted to offer silver-coated vascular grafts, as they are designed to resist infection. The acquired portfolio posted 2025 sales of 9.4 million, all outside North America. 65% of sales were in Europe, including 21% in Germany, our second largest market. While the sales transition will take about two years, this acquisition is right out of our playbook. We acquire niche vascular and cardiac products and grow them through our global sales channel. As for Autograph, we're investing in the product in several ways. Number one, more international approvals. Number two, increased length for leg bypasses. And number three, building out our commercial infrastructure and sales force. Q3 international autograph sales were $3 million, and we continue to expect full-year sales of more than $11 million. In Q3, we received approvals in Brazil and Saudi Arabia, bringing us to 60 countries. We expect 2027 approvals in Korea and India. We plan to apply to the PMDA in Japan this quarter, hoping for 2029 or 2030 approval. We're also developing long autographs for leg bypasses. Unfortunately, our autograph packaging is too short for these long graphs. We plan to submit for US and CE mark long tube approval in Q4, 2026. First sales could start in H2, 2027. On October 7th, we attended an encouraging FDA virtual meeting regarding our New Jersey autograph facility. The agency is reviewing our responses to their observations. The observations from the two FDA inspections have not disrupted our ability to produce, ship, or invoice. An FDA reinspection is likely in 2027. Restorfo Allograft revenues grew 34% in Q3. We're approved to distribute these cadaver tissues in six countries, the US, Canada, New Zealand, the United Kingdom, Austria, and Germany. And we're actively working to gain approvals in four countries in 2027. Holland, Ireland, Spain, and Switzerland. We still plan to close our Chicago RestoreFlow facility this year and fully transfer production to Burlington. We continue to expand our commercial infrastructure. Rep count increased by 19 year-over-year to 171 at Quarters End. Our American and German territories continue to grow, requiring us to split territories. We now plan to open a Polish office and warehouse in Q1, 2027. We also plan to open a Malaysian office and warehouse in 2027. Indeed, seven new or larger LeMaitre International warehouses are opening in 2026 slash 2027. These offices place LeMaitre products closer to our hospital customers and provide local customer service. We also recently expanded our Burlington footprint by adding a 30,000 square foot building. We gain access to the building in July 2027 and expect to use the space to consolidate our Burlington manufacturing operations and provide capacity to integrate manufacturing from acquisitions. Per our recent 8K, 2026 will be Dave Roberts' last year as our president, though he'll remain on our board as elected by our shareholders. In his 30 years at LeMaitre, Dave navigated our 2006 IPO as CFO and spearheaded 26 acquisitions. Of course, these are big shoes to fill professionally. We've begun recruiting additional senior-level biz dev executives. In the short run, I'll be heading up our biz dev group, and we will remain an acquisitive company. In other personnel news, I'd like to welcome Tarek Pachuca to LeMaitre as our new global head of marketing and worldwide export. Tarek joined in August after 16 years at Tarumo Aortic, where he was the chief commercial officer. to rheumatoid aortic cells approximately $375 million a year of polyester grafts and stent grafts, and as a common call point with LeMaitre, vascular and cardiac surgeons. To conclude, 12% organic growth was driven by price and unit growth, the international autograph launch, restore flow growth, and our expanding sales force. Our 26% Q3 op margin as well as our 27% ROIC underscores our underlying profitability. Full year guidance implies 11% organic sales growth, 11% reported sales growth, and 18% EPS growth. I'll now turn the call over to Dorian.
You're reading a preview of the LMAT Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing